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Key questions
What is already known?
 ► The Global Burden of Disease study estimates 
changes in disease burden for specific diseases, 
disease groups or risk factors for more than two de-
cades from 1990 to 2017.
 ► Indices to estimate relative and absolute inequality 
such as the Gini Index and the Slope Inequality Index 
have been used in the context of health, so far how-
ever have been applied only to national or sub-na-
tional data for disease specific analysis.
 ► How changes in disease burden affects be-
tween-country global health inequality, however, 
remains a matter of debate.
What are the new findings?
 ► Applying the Gini Index (for relative inequality) and 
Slope Inequality Index (for absolute inequality) to 
diseases and disease groups allows a deeper un-
derstanding of the extent, structure and evolution of 
global health inequality.
 ► Absolute between-country inequality of all causes of 
disease decreased between 1990 and 2017, while 
relative inequality remained stable.
 ► On a more granular level, our data can also help to 
assess areas of concern, such as disease groups 
for which inequality has increased in recent years, 
and can highlight achievements, where progress 
has been made towards a reduction of global health 
inequality.
What do the new findings imply?
 ► If progress in the reduction of health inequality be-
tween nations is to be sustained beyond the global 
epidemiological transition, the fight against commu-
nicable disease and injuries must therefore continue 
and be joined by increased efforts for NCDs.
AbsTrACT
background The major shifts in the global burden of 
disease over the past decades are well documented, 
but how these shifts have affected global inequalities 
in health remains an underexplored topic. We applied 
comprehensive inequality measures to data from the 
Global Burden of Disease (GBD) study.
Methods Between-country relative inequality was 
measured by the population-weighted Gini Index, between-
country absolute inequality was calculated using the 
population-weighted Slope Inequality Index (SII). Both were 
applied to country-level GBD data on age-standardised 
disability-adjusted life years.
Findings Absolute global health inequality measured by 
the SII fell notably between 1990 (0.68) and 2017 (0.42), 
mainly driven by a decrease of disease burden due to 
communicable, maternal, neonatal and nutritional diseases 
(CMNN). By contrast, relative inequality remained essentially 
unchanged from 0.21 to 0.19 (1990–2017), with a peak of 
0.23 (2000–2008). The main driver for the increase of relative 
inequality 1990–2008 was the HIV epidemic in Sub-Saharan 
Africa. Relative inequality increased 1990–2017 within each 
of the three main cause groups: CMNNs; non-communicable 
diseases (NCDs); and injuries.
Conclusions Despite considerable reductions in disease 
burden in 1990–2017 and absolute health inequality 
between countries, absolute and relative international 
health inequality remain high. The limited reduction of 
relative inequality has been largely due to shifts in disease 
burden from CMNNs and injuries to NCDs. If progress 
in the reduction of health inequalities is to be sustained 
beyond the global epidemiological transition, the fight 
against CMNNs and injuries must be joined by increased 
efforts for NCDs.
InTroduCTIon
Major shifts have taken place in the global 
burden of disease over the past 25 years. In 
the literature, disagreement exists on how 
these shifts have affected health inequality on 
a global level.1–5 Here, we apply two univariate 
measures of inequality—the Gini Index (for 
relative inequality), and the Slope Inequality 
Index (SII; for absolute inequality)—to 
age-standardised country-level disease burden 
data from the Global Burden of Disease (GBD) 
study, to quantify changes in global between-
country inequality in disease burden from 1990 
to 2017.6
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The Gini Index and SII are widely used to measure 
inequality in the distribution of economic resources 
such as income or wealth.7 8 To our knowledge, in the 
context of health, these measures have previously been 
applied only to national or sub-national data, within 
disease-specific analyses, and to mortality and life expec-
tancy data.9–13
By applying them, for the first time, to disease burden 
data measured in disability-adjusted life years (DALYs) 
for all disease groups and across all countries, we arrive 
at estimates for overall global health inequality that have 
not previously been available.
With this study we aim to identify and add evidence 
on the key drivers of global health inequality. Health 
inequality has been defined by Braveman as a ‘difference 
in health or in the most important influences on health 
that could potentially be shaped by policies; it is a differ-
ence in which disadvantaged social groups […] systemati-
cally experience worse health or greater health risks than 
more advantaged social groups’.14
In this analysis, we aim to add to the evidence on how 
major epidemiological events such as the HIV epidemic, 
war and natural disasters are affecting those differences 
in health, and how the relative health status of advan-
taged and disadvantaged countries has changed over 
time. Quantifying global health inequality can help to 
assess progress, or the lack thereof, and help to identify 
challenges and opportunities for reducing global health 
inequalities.
MeTHods
A range of statistical methods can be employed to 
analyse disparities in the distribution of health, such as 
life expectancy, disease burden, treatments and research 
efforts.9 15–17 We used the population-weighted Gini Index 
to measure relative health inequality, and the popula-
tion-weighted SII to measure absolute inequality. We 
calculated these indices for country-level disease burden 
data measured in age-standardised DALYs per capita, as 
provided by the GBD study, for every year in the time 
period 1990 to 2017.6 18
The DALY is a composite measure for population 
health, calculated by summing years of life lost to prema-
ture death and years of healthy life lost due to disability.6 
Years of life lost to premature death are calculated based 
on a theoretical life expectancy of 86 years. Years of 
healthy life lost due to disability are calculated by multi-
plying the number of years lived with a specific health 
condition with the respective disability weight which is 
a factor ranging from 0 to 1, representing the severity 
of the disability associated with this condition. DALYs 
are generally considered the best available measure for 
overall population health.6
As our focus is health inequality due to differences in 
health systems, risk factors and socioeconomic factors, we 
used age-standardised DALYs to minimise confounding by 
differences in the age structures of different populations. 
Age-standardised DALYs, adjust country-level disease 
burden for the country’s population age structure by 
weighting disease burden in each age category to fit a 
‘standard population’ (the GBD study designs its own 
standard population).6 We calculated the population of 
the countries in each year from the number of deaths in 
a country and the relative death rate across all ages.
We used GBD disease classification of level 1 cause 
groups—communicable, maternal, neonatal and nutri-
tional diseases (CMNNs), non-communicable diseases 
(NCDs) and injuries—and the 21 level 2 cause groups. 
For some level 2 disease groups, we moved to a more 
granular level of classification in order to increase clarity. 
For example, instead of assessing the level 2 classifica-
tion ‘A.1 HIV/AIDS and sexually transmitted infections’, 
we considered the two level 3 categories it consists of, 
namely ‘A.1.1. HIV/AIDS’ and ‘A.1.2. sexually trans-
mitted diseases excluding HIV’.
The Gini Index is derived from the Lorenz curve, 
which plots for each country the cumulative share of the 
global disease burden against the cumulative share of the 
world population, ordered by ascending DALY rate. The 
Gini Index is calculated as twice the area bounded by the 
Lorenz curve and a theoretical egalitarian distribution, 
represented as the function y=x (online supplementary 
appendix, figures 1 and 2). When applied to the DALY 
rate, the Gini Index expresses the average relative differ-
ence in the disease burden between any two of the 195 
countries included in the dataset. It can range from 0 
in total equality, where all countries exhibit the same 
disease burden per capita, to 1 in total inequality, with 
all disease burden concentrated in a single country.9 We 
used the population-weighted Gini Index to account for 
the heterogeneity of countries with respect to population 
size. Without weighting for population size, countries 
with a small population would influence the value of the 
Gini Index as much as countries with a large population.19
The derivation of the SII is based on the Pen’s Parade. 
The Pen’s Parade is derived from ranking all countries by 
their DALY rate from highest to lowest, with their share 
of the world’s population as the width of a ‘step’ on the 
horizontal axis. The SII is the coefficient (slope) of the 
linear regression of this Pen’s Parade (online supplemen-
tary appendix, figures 3 and 4), and can be interpreted 
as a measure for the average absolute difference in DALY 
rates between countries.20
The Gini Index and the SII are univariate measures 
of inequality which capture the disparity in the distribu-
tion of one specific resource—in our case health. Bivar-
iate measures of inequality, by contrast, capture how two 
different resources—(eg, income and health) are related 
to each other.21 We focus on univariate measures of 
inequality, as we aim to capture inequality of health per 
se, rather than the relationship between health and other 
resources.
In order to capture the uncertainty in the underlying 
data set, we additionally calculated the upper and lower 
uncertainty bound based on the 95% CI in the GBD data. 
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Figure 1 Gini Index for all-cause and level 1 cause group 
DALY rates.The Gini Index was highest for CMNNs and 
lowest for NCDs. For both all-cause DALY rate and CMNNs, 
Gini increased until 2006/2007, and decreased subsequently 
until 2017. For injuries, peaks can be seen in 1994 due to 
the genocide in Rwanda and in 2010 due to the earthquake 
in Haiti. CMNN, communicable, maternal, neonatal and 
nutritional diseases; DALY, disability-adjusted life years lost; 
NCD, non-communicable diseases.
Figure 2 Slope Inequality Index for all-cause and level 
1 cause group DALY rates. SII was highest for all-cause 
DALYs than for any of the individual level 1 cause groups and 
decreased between 1990 and 2017. Similarly for CMNN, SII 
decreased following the same trend as seen for all-cause 
DALY SII. The SII for NCDs showed a slight increase whereas 
for injuries a slight decrease was marked. For injuries, peaks 
can be seen in 1994 due to the genocide in Rwanda and in 
2010 due to the earthquake in Haiti. CMNN, communicable, 
maternal, neonatal and nutritional diseases; DALY, disability-
adjusted life years lost; NCD, non-communicable diseases.
For each country in each year, we chose the value within 
the 95% CI closest to the global population-weighted 
median for the low-inequality scenario (lower bound), 
and the value within the 95% CI furthest from the 
median in the high inequality scenario (upper bound). 
Thereby, the bounds express the highest and lowest value 
the inequality indicators can reach based on the 95% CI 
in the GBD data.
All calculations were conducted in R V.3.5.0, using the 
ineq package V.0.2–13.22 23
Patient and public involvement statement
No patients or the general public were involved in the 
analysis.
resulTs
The change in Gini Index and the SII for all-cause, 
CMNN, NCD and injuries for DALY rates between 
1990 and 2017 are visualised in figures 1 and 2 . Table 1 
summarises the respective numbers. The graphical 
representation of the distribution of the disease burden 
(measured as age-standardised DALY rate per 100 000) is 
shown as population boxplots in the online supplemen-
tary appendix, figures 5 and 6.
The Gini Index for all-cause DALY rate increased 
between 1990 (0.21 (0.18 to 0.24)) and 2008 (0.23 (0.19 
to 0.26)), followed by a decrease starting in 2009 to 0.19 
(0.16 to 0.23) in 2017 (figure 1). Relative inequality in 
the injuries and NCD cause groups was much lower than 
in the CMNN cause group. The Gini Index for CMNN 
increased from 0.47 (0.45 to 0.49) in 1990 to 0.52 (0.50 
to 0.53) in 2010, followed by a decline to 0.49 (0.47 to 
0.52) by 2017. The Gini Index increased steadily for 
NCDs between 1990 (0.07 (0.05 to 0.11)) and 2017 (0.10 
(0.07 to 0.14)), and for injuries (0.15 (0.14 to 0.18) to 
0.18 (0.16 to 0.20)). For injuries, local peaks can be seen 
in 1994 due to the genocide in Rwanda and in 2010 due 
to the earthquake in Haiti (figures 1 and 2).
The development of the Gini Index for the more gran-
ular level 2 disease groups for 1990 and 2017 is shown 
in figure 3. Unlike the overall trend in CMNN, HIV/
AIDS and nutritional deficiencies showed a substantial 
decrease in Gini Index. For NCDs, a decrease in Gini 
Index was solely observed for chronic respiratory disease 
and neoplasms.
In contrast, absolute inequality, as measured by the SII, 
was higher for all-cause DALYs than for any of the indi-
vidual level 1 cause groups, reflecting the higher absolute 
between-country differences in all-cause DALY rates than 
in DALY rates for individual disease groups (figure 2). 
The SII decreased markedly for all-cause DALY rates 
from 0.68 (0.56 to 0.79) in 1990 to 0.42 (0.35 to 0.51) in 
2017. For the CMNN cause group, similarly, SII decreased 
from 0.55 (0.51 to 0.62) to 0.28 (0.24 to 0.32), following 
a very similar curve to the all-cause DALY SII. While the 
SII for NCDs remained essentially unchanged (from 0.12 
(0.08 to 0.19) to 0.13 (0.10 to 0.19)), the SII for injuries 
fell significantly (from 0.07 (0.06 to 0.07) to 0.04 (0.03 
to 0.05)). Excluding outliers from the dataset (Rwanda 
1993 and 1994, Haiti 2010) showed that the SII in 
all-cause DALYs and injuries followed the general trend 
of the respective curves, explaining the severe effect of 
these humanitarian disasters on absolute inequality of 
all-cause DALYs.
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Figure 3 Changes in Gini Index for level 2, and selected 
level 3 disease groups between 1990 and 2017. Unlike HIV/
AIDS and malaria, chronic respiratory diseases, enteric 
infections and neoplasms, the Gini Index of the subgroups 
followed the general trend of increasing relative inequality. 
STI, sexually transmitted infection, NTD, neglected tropical 
diseases.
dIsCussIon
Despite global age-standardised DALY rates steadily 
decreasing both for all-cause disease burden and for 
level 1 cause groups (table 1), absolute inequality in 
disease burden remains high. In countries with the lowest 
burden of disease per capita, less than 20% of the poten-
tial healthy lifetime of individuals was lost to ill health in 
2017, whereas more than 70% of potential healthy lifetime 
was lost in countries with the highest burden of disease 
per capita (online supplementary appendix, figure 3). 
The SII of 0.42 (0.35 to 0.51) for all-cause DALYs in 2017 
can be interpreted as meaning that for every decile one 
moves down in global population ranked by increasing 
health burden, on average an additional 4% of healthy 
life time is lost.
Relative global health inequality, measured by the Gini 
Index, is also high. The Gini Index for disease burden 
was lower in 2017 (0.19 (0.16 to 0.23)) than in the peak 
period between 2000 and 2008 (0.23 (0.19 to 0.26)) 
as well lower than in 1990 (0.21 (0.18 to 0.24)), repre-
senting a progress of 2% towards equality on the scale of 
total inequality to total equality, over 27 years. Moreover, 
the small magnitude of this change casts doubt on the 
overall plausibility that a relevant reduction in relative 
inequality has occurred: in economics, a threshold of 3% 
(the ‘Atkinson salience criterion’) has been used to deter-
mine the significance of temporal changes in the Gini 
Index for economic resources such as income24 25 which 
the observed changes in Gini Index for all-cause DALYs 
did not exceed. As a point of comparison, inequality in 
healthy lifetime is nearly as high as income inequality 
among individuals in Organization for Economic Coop-
eration and Development (OECD) countries (Gini Index 
0.32 in 20148) but lower than income inequality globally 
(Gini Index 0.65 in 201326).
Relative and absolute inequality have exhibited 
diverging trends (figures 1 and 2). While the Gini Index 
did not change significantly from 1990 (0.21 (0.18 to 
0.24)) to 2000–2008 (0.23 (0.20 to 0.26)) to 2009–2017 
(0.19 (0.16 to 0.23)), absolute inequality fell slowly 
between 1990 and around 2006 (0.68 (0.56 to 0.79) 
to 0.62 (0.53 to 0.73)) subsequently decreasing more 
rapidly until 2017 to an SII of 0.42 (0.53 to 0.51). Abso-
lute inequality fell faster and more pronouncedly than 
relative inequality.
We observed decreasing absolute inequality with essen-
tially unchanged relative inequality. Arithmetically, this 
combination occurs when the disease burden decreases 
at similar rates in countries with high and low baseline 
burdens, resulting in unchanged relative inequality, 
but falling absolute inequality.27 Braveman’s ethical 
framework does not specifically distinguish how abso-
lute versus relative inequality metrics reflect on health 
(in)equity. However, the depicted decrease in absolute 
inequality may represent a ‘levelling up’ in Braveman’s 
ethical framework, while the lack of reduction in relative 
inequality may reflect Braveman’s caution that pursuing 
equity requires ‘reducing unfair disparities as well as 
meeting acceptable standards’.28
Cause group sub-analyses
Absolute and relative inequality is highest for CMNNs, 
and lowest for NCDs and injuries (table 1).
Considering the Gini indices for individual cause groups 
shows that despite the marginal decrease in Gini Index 
for all-cause DALYs, discussed above, relative inequality 
has risen in each of the three ‘level 1’ cause groups indi-
vidually (figures 3 and 4). In contrast, absolute inequality 
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Figure 4 Trends in Gini and SII between 1990 and 2017 for 
all causes, CMNNs, injuries and NCDs. Subgroup analysis 
reveals an increase in relative inequality and a decrease for 
absolute inequality for CMNNs and injuries between 1990 
and 2017. CMNN, communicable, maternal, neonatal and 
nutritional diseases; NCD, non-communicable diseases; SII, 
Slope Inequality Index.
decreased markedly for CMNNs (SII 0.55 (0.51 to 0.62) 
in 1990 to 0.28 (0.24 to 0.32) in 2017), and less markedly 
for injuries (SII 0.07 (0.06 to 0.07) in 1990 to 0.04 (0.03 
to 0.05) in 2017), but increased for NCDs (SII 0.12 (0.08 
to 0.19) in 1990 to 0.13 (0.10 to 0.19) in 2017) (figure 4).
The finding of a reduction in all-cause relative inequality 
1990–2017 (figures 3 and 4) despite increases in the 
relative inequality for each individual level 1 subgroup 
(NCDs, CMNNs and injuries) may be explained by the 
fact that CMNNs have greater relative inequality across 
years, and 9% of global all-cause DALYs have shifted 
from this group to NCDs which had a lower baseline 
inequality level (table 1 and figure 4). This suggests that 
the decrease in overall, all-cause relative health inequality 
seen between 1990 and 2017 was driven mainly by a 
global shift of the disease burden from CMNNs and inju-
ries to NCDs, and not by declining relative inequality for 
either CMNNs, injuries or NCDs. What derives from this 
interpretation is that as NCDs take an increasing propor-
tion of the global burden of disease, the slight decrease 
observed for all-cause relative inequality over the past 25 
years may stall or reverse unless ways are found to tackle 
inequality in the distribution of NCDs.
Analysis of inequality trends on the level of the more 
detailed level 2 cause groups of the GBD study revealed 
substantial heterogeneity within the three major level 1 
cause groups (figure 3). For NCDs, relative inequality has 
decreased for some level 2 cause groups, such as chronic 
respiratory disease and neoplasms, but this has been 
offset by an increase in inequality for others, most mark-
edly cardiovascular disease. In certain disease groups, 
further disaggregation is necessary to discern relevant 
trends: For example, within the group of urogenital, 
blood and endocrine disorders, relative inequality has 
increased markedly for diabetes, while it has decreased 
for most haematological disorders (data not shown).
The marginal rise in relative inequality for NCDs may 
be interpreted as follows. While for some NCDs, raw 
incidence figures are higher in high-income than in 
middle-income and low-income countries, this is not the 
case when using age-standardised DALY rates, as we do 
in our analysis: when adjustments for the different age 
structures of populations are made, the disease burden 
per capita caused by NCDs is higher in low-income and 
middle-income countries than in high-income countries 
(online supplementary appendix, figure 7). While all 
income groups have seen reducing age-standardised NCD 
DALY rates, progress is more pronounced in high-in-
come countries than in low-income and middle-income 
countries (online supplementary appendix, figure 7). 
This implies that the epidemiological transition does 
not necessarily have an equalising effect on the global 
NCD burden. To the contrary, the persistent absolute 
and relative inequality in the distribution of NCDs across 
the globe disadvantages the same countries which are 
also more generally deprived. Further reductions in 
DALY rates for CMNN and Injuries would be expected 
to eventually manifest in lower relative inequality (Gini 
values) for these groups—despite rises from 1990 to 2017 
(table 1, figure 1)—if and when the rate of decrease in 
the highest-burden countries equals or exceeds that in 
lower-burden countries.27
Policy implications
As discussed above, the marginal decline in Gini Index 
since 1990 has been largely driven by shifts between major 
disease groups and decreases in absolute inequality have 
been largely driven by a decrease of the average global 
DALY rate. In contrast, there have not been significant 
declines in relative inequality for the three major cause 
groups considered individually.
For NCDs, absolute and relative inequality levels have 
been stagnant at the global level, and have increased 
for the cardiovascular disease and diabetes subgroups. 
As NCDs represent a growing proportion of the global 
burden of disease, global health inequality will increas-
ingly be determined by inequality in NCDs.
In high-income countries, progress in the preven-
tion and control of NCDs has been made both through 
preventive efforts such as effective tobacco control poli-
cies, increased intake of essential nutrients and increasing 
leisure-time physical activity and through easily scalable 
medical interventions, such as treatment of hyperten-
sion, dyslipidaemia and hyperglycaemia.29 Such efforts 
in the prevention and control of NCDs must be scaled 
up, strengthened and adapted to the specific needs of 
low-income and middle-income countries if overall prog-
ress in the reduction of cross-country health inequality 
is to be sustained beyond the global epidemiological 
transition.29 30 Furthermore, increased efforts have to be 
made in tackling risk the NCD risk factors of household 
and ambient air pollution, which are of particular high 
relevance in low and middle income countries.18 31 32 
However, significant research and funding gaps exist for 
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NCD programme implementation in low- and middle-in-
come countries.33 34 NCDs received less than 2% of 
development assistance for health in 2016 (authors’ 
own calculation, using data reported by the Institute for 
Health Metrics and Evaluation).35 While data on domestic 
NCD funding is scarce, in 2013, 50% of countries did not 
have a national NCD policy with a budget for implemen-
tation.36 The WHO has argued that the cost of inaction 
exceeds the cost of action in economic terms, and that a 
basic basket of public health interventions is cost-effec-
tive and affordable for all countries—costing less than 
US$0.20 per person per year in low-income countries, 
and US$0.50 in middle-income countries.37 38
At the same time, in order to reduce inequality, efforts 
to reduce CMNN burden must at minimum sustain the 
rate of decrease seen over the last 27 years. Political 
commitment continues to be key: for example, funding 
for the global response to HIV/AIDS will need to increase 
by about a third in the coming years in order to stem the 
epidemic by 2030.39
limitations
Since we use country-level disease burden data, our anal-
ysis does not capture within-country inequality which can 
be substantial17 40: for example, one study using height 
of children as an anthropometric indicator of general 
health found that between-country inequality comprises 
26%, and within-country inequality 74% of total global 
health inequality.17
While DALYs are a widely used measure of general 
health status, their calculation relies on a number of 
methodological assumptions and value judgements which 
are subject to debate.6 41 Similarly, while the GBD study is 
generally considered the most comprehensive and reli-
able source for global DALY data, there are limitations to 
its data, such as unreliable and missing data, in particular 
for low-income and middle-income countries.6
There are a number of inherent limitations to the 
Gini Index and the SII. They are univariate measures of 
inequality, implying that they provide no information 
on correlations of disparities in health with other social 
indicators.14 Moreover, the Gini Index and the SII do not 
demonstrate transfer sensitivity, meaning that changes 
at the upper end of the distribution are given the same 
weight as changes at the lower end of the distribution.6 
The Gini Index in particular is sensitive to the number 
of observations affected by a change which can make 
it disproportionately sensitive to changes around the 
median (where the number of observations is generally 
higher), meaning that the effect of changes in the DALY 
burden of countries most deprived in health terms may 
be under-weighted.7
Lastly, there are limitations to our comparison of least-
healthy to most-healthy, rather than a comparison based 
on wealth. As Braveman notes: ‘abandoning the compar-
ison between social strata in favour of a comparison with 
the healthiest runs the risk [of removing] distributive 
justice issues from consideration and hence from the 
policy agenda’.14
ConClusIons
Despite considerable progress in reducing disease 
burden and absolute inter-country inequality over the 
past 25 years, absolute inequality in health across coun-
tries remains high and relative inequality in age-stand-
ardised all-cause DALY-rates has decreased only margin-
ally since 1990. The reduction in absolute global inter-
country health inequality during the past 25 years has 
been largely a resulst of a decrease in the total global 
disease burden, rather than of changes to the distribu-
tion of the disease burden across countries. Minor reduc-
tions in relative global inter-country health inequality 
observed since 2008 have been driven by a global shift 
from communicable diseases to NCDs and injuries, while 
inequality has remained stable or risen for these three 
cause groups considered separately. If progress in the 
reduction of health inequality between nations is to be 
sustained beyond the global epidemiological transition, 
the fight against communicable disease and injuries must 
therefore continue and be joined by increased efforts for 
NCDs.
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